• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aziyo Biologics Inc. (Amendment)

    2/14/23 4:52:30 PM ET
    $AZYO
    Medical Specialities
    Health Care
    Get the next $AZYO alert in real time by email
    SC 13G/A 1 endurant13g2AZYO12.31.2022.htm ENDURANT13G2AZYO Schedule 13G
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ____2____)*

    Aziyo Biologics, Inc.

    (Name of Issuer)

    Class A Common Stock, $ 0.01 par value

    (Title of Class of Securities)

    05479K106

    (CUSIP Number)

    Endurant Capital Management LP
    66 Bovet Road, Suite 353
    San Mateo, CA 94402
    650-539-5905

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    12/31/2022

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    þ  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    CUSIP No. 05479K106   13G  
         
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Endurant Capital Management LP
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    þ
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    00,000
      6.   SHARED VOTING POWER
     
    1,259,544
      7.   SOLE DISPOSITIVE POWER
     
    00,000
      8.   SHARED DISPOSITIVE POWER
     
    1,259,544
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,259,544
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨


       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    10.67%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    OO, IA
       
     
     

    CUSIP No. 05479K106   13G  
         
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Quang Minh Pham
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    þ
       
    3.   SEC USE ONLY
     
       
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA

     

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    00,000
      6.   SHARED VOTING POWER
     
    1,259,544
      7.   SOLE DISPOSITIVE POWER
     
    00,000
      8.   SHARED DISPOSITIVE POWER
     
    1,259,544
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,259,544
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨


       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    10.67%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IN, HC
       
     
     
    CUSIP No. 05479K106   13G  

     

     

         

    Item 1.

      (a) Name of Issuer
    Aziyo Biologics, Inc.
     
      (b) Address of Issuer’s Principal Executive Offices
    12510 Prosperity Drive, Suite 370
    Silver Spring, MD 20904
     

    Item 2.

      (a) Name of Person Filing
    Endurant Capital Management ,LP, a Delaware limited partnership with respect to the shares of Class A Common Stock directly held by Endurant Health Fund LP (“Endurant Onshore”), Endurant Health Offshore Fund Ltd. (“Endurant Offshore”), Endurant Fund Master LP (“Endurant Master” and together with Endurant Onshore and Endurant Offshore, the “Endurant Investment Funds”), Molecule Master, LP, One Oak Multi-Strategy Master Fund, Ltd. and PM Manager Fund, SPC, (the “Endurant Sub-Advised Funds”);

    Mr. Quang Minh Pham, as managing member of Endurant Capital Management LP, with respect to the Class A Common Stock directly held by each of the Endurant Investment Funds and Endurant Sub-Advised Funds.

    Endurant Capital Management LP serves as the investment manager to, and has investment discretion over the securities held by, the Endurant Investment Funds and the Endurant Sub-Advised funds. Mr. Quang Minh Pham is the only managing member of Endurant Capital Management LP.

    The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

    The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Class A Common Stock reported herein.
     
      (b) Address of the Principal Office or, if none, residence
    66 Bovet Road, Suite 353
    San Mateo, CA 94402
     
      (c) Citizenship
    Endurant Capital Management LP is a limited partnership organized under the laws of the State of Delaware. Mr. Quang Minh Pham is a United States citizen.
     
      (d) Title of Class of Securities
    Class A Common Stock, $0.01 par value
     
      (e) CUSIP Number
    05479K106
     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
      (e) þ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) þ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
     

    Item 4.  Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

      (a)   Amount beneficially owned:  1,259,544
     
      (b)   Percent of class:  10.67%
     
      (c)   Number of shares as to which the person has:  
     
          (i) Sole power to vote or to direct the vote  .
     
          (ii) Shared power to vote or to direct the vote  1,259,544.
     
          (iii) Sole power to dispose or to direct the disposition of  .
     
          (iv) Shared power to dispose or to direct the disposition of  1,259,544.
     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     ¨.

    Instruction. Dissolution of a group requires a response to this item.

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Item 8.  Identification and Classification of Members of the Group.

     

    Item 9.  Notice of Dissolution of Group.

     

    Item 10.  Certification.

      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
     
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
      (b)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
     
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
     
    CUSIP No. 05479K106   13G  

     

     

         

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    02/14/2023

    Date

    /s/ Quang Minh Pham

    Signature

    Quang Minh Pham - Managing Member

    Name/Title

    Get the next $AZYO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZYO

    DatePrice TargetRatingAnalyst
    3/4/2022$15.00 → $13.00Outperform
    Cowen & Co.
    More analyst ratings

    $AZYO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference

      SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET. A live webcast of the presentation can be accessed by visiting the Company's Events & Presentations webpage or by clicking here. A replay will be available on the Company's website following the event. Institutional investors interested in meeting with management during the conference may reach out

      9/8/23 8:30:00 AM ET
      $AZYO
      $ELUT
      Medical Specialities
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices

      – Company to begin trading under new ticker symbol "ELUT" – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo") today announced a change of the Company's name to Elutia Inc. The rebranding reflects the strategic focus to develop and commercialize proprietary drug-eluting biomatrix technology aimed at improving surgical outcomes. The name change becomes effective today, September 6, 2023. The Company's stock will begin trading on Nasdaq under the new ticker symbol "ELUT" on September 7, 2023. "We are excited to introduce Elutia, where we exist to humanize medicine by pioneering drug-eluting biomatrix or DEB technology," said Dr. Randy Mills

      9/6/23 4:05:00 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures

      Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced the publication of a case report highlighting results that demonstrate the potential benefits of using a biological device envelope during reoperative procedures for CIEDs. The report, titled "Rehabilitation of an Existing Device Implant Pocket Using a Biolog

      8/30/23 8:30:00 AM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen & Co. reiterated coverage on Aziyo Biologics with a new price target

      Cowen & Co. reiterated coverage of Aziyo Biologics with a rating of Outperform and set a new price target of $13.00 from $15.00 previously

      3/4/22 9:16:21 AM ET
      $AZYO
      Medical Specialities
      Health Care